ArticleCureus2025
Predictive Value of Procalcitonin and C-reactive Protein for Mortality in Live Donor Liver Transplant Recipients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate biomarkers are crucial for the early diagnosis of sepsis after liver transplantation. This study aimed to evaluate the diagnostic accuracy of procalcitonin (PCT) and C-reactive protein (CRP) in predicting bacterial infections and mortality following living donor liver transplantation (LDLT). METHODOLOGY: We prospectively analyzed all adult LDLT patients at a tertiary center between January 2021 and December 2022. CRP and PCT levels were measured on postoperative days (POD) one, three, five, and seven, and compared among patients without infections, those with bloodstream infections, and those with other infections (urinary, bronchoalveolar lavage, or drain). Multivariate logistic regression assessed the impact of PCT and CRP trends on short- and long-term mortality.
resultsAmong 216 LDLT patients, 122 (56%) were analyzed after applying exclusion criteria. In patients without infections, median CRP and PCT levels were elevated on days one (CRP: 19, interquartile range (IQR): 11-29; PCT: 3, IQR: 1-13) and three (CRP: 18, IQR: 7-30; PCT: 2, IQR: 1-9) but decreased by days five (CRP: 10, IQR: 5-16; PCT: 1, IQR: 0.2-3) and seven (CRP: 10, IQR: 3-17; PCT: 0.7, IQR: 0.3-3). No absolute values of CRP or PCT effectively diagnosed infections. Patients with a decreasing trend in CRP from POD three to five to seven had survival rates of 90%, 86%, and 85% at 30, 90, and 600 days, respectively; in contrast, those with an increasing CRP trend had lower survival rates of 78%, 71%, and 40%, respectively. Similarly, a decline in PCT was associated with 30-, 90-, and 600-day survival rates of 90%, 85%, and 84%, while increasing PCT correlated with significantly lower rates of 75%, 70%, and 30%, respectively.
conclusionWhile the absolute values of CRP and PCT were not diagnostic for infection, an increase in these biomarkers from days three to five to seven predicted significantly higher short- and long-term mortality in LDLT recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.